Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 49

Results For "oncology"

751 News Found

Laurus Labs takes stake in Ethan Energy India
News | November 25, 2022

Laurus Labs takes stake in Ethan Energy India

This will enable the company to consume 100% of the solar energy to be supplied by Ethan Energy India Private Limited from their 10 MW Solar Energy plant


Biocon enters commercialization agreement with Zentiva
News | November 24, 2022

Biocon enters commercialization agreement with Zentiva

Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe


Evive enters license agreement with Acrotech Biopharma to commercialize Ryzneuta in US
News | November 24, 2022

Evive enters license agreement with Acrotech Biopharma to commercialize Ryzneuta in US

Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)


SRL Diagnostics hosts ‘International Gynecologic & Breast Cancer Symposium 2022’
News | November 23, 2022

SRL Diagnostics hosts ‘International Gynecologic & Breast Cancer Symposium 2022’

Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India


Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast
Healthcare | November 18, 2022

Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast

Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning


Lynparza in combination with Abiraterone and prednisone receives positive opinion from EU CHMP
Drug Approval | November 15, 2022

Lynparza in combination with Abiraterone and prednisone receives positive opinion from EU CHMP

First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations


YS Biopharma announces USFDA clearance of IND Application for PIKA COVID-19 vaccine
Drug Approval | November 11, 2022

YS Biopharma announces USFDA clearance of IND Application for PIKA COVID-19 vaccine

PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.


USFDA determines inspection classification of Jubilant Pharmova's Roorkee facility
News | October 31, 2022

USFDA determines inspection classification of Jubilant Pharmova's Roorkee facility

The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue


Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial
Diagnostic Center | October 27, 2022

Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial

Results reinforce commitment to next-generation oral SERD development programme


ERES IV acquires a majority stake in Oncodesign Services
News | October 27, 2022

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.